BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Pinxteren B, Numans M, Bonis P, Lau J, Numans M. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd002095.pub2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;CD001216. [PMID: 17253456 DOI: 10.1002/14651858] [Cited by in Crossref: 2625] [Cited by in F6Publishing: 769] [Article Influence: 175.0] [Reference Citation Analysis]
2 Vakil N, Björck K, Denison H, Halling K, Karlsson M, Paty J, Silberg DG, Rydén A. Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol 2012;3:e7. [PMID: 23238029 DOI: 10.1038/ctg.2012.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
3 Jozkow P, Wasko-Czopnik D, Medras M, Paradowski L. Gastroesophageal reflux disease and physical activity. Sports Med. 2006;36:385-391. [PMID: 16646627 DOI: 10.2165/00007256-200636050-00002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
4 Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16:8-21. [PMID: 20535321 DOI: 10.5056/jnm.2010.16.1.8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 7.1] [Reference Citation Analysis]
5 Gawrieh S, Shaker R. Medical management of nocturnal symptoms of gastro-oesophageal reflux disease in the elderly. Drugs Aging 2003;20:509-16. [PMID: 12749748 DOI: 10.2165/00002512-200320070-00003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Oridate N, Takeda H, Asaka M, Nishizawa N, Mesuda Y, Mori M, Furuta Y, Fukuda S. Acid-suppression therapy offers varied laryngopharyngeal and esophageal symptom relief in laryngopharyngeal reflux patients. Dig Dis Sci. 2008;53:2033-2038. [PMID: 18080197 DOI: 10.1007/s10620-007-0114-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
7 Nagahara A, Suzuki T, Nagata N, Sugai N, Takeuchi Y, Sakurai K, Miyamoto M, Inoue K, Akiyama J, Mabe K. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. J Gastroenterol. 2014;49:1536-1547. [PMID: 24366288 DOI: 10.1007/s00535-013-0925-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
8 van Zanten SJ, Henderson C, Hughes N. Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can J Gastroenterol 2012;26:196-204. [PMID: 22506259 DOI: 10.1155/2012/235476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 Rydén A, Martin M, Halling K, Niklasson A. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study. Patient. 2013;6:307-314. [PMID: 23990378 DOI: 10.1007/s40271-013-0024-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;CD002095. [PMID: 23728637 DOI: 10.1002/14651858.cd002095.pub5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
11 Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, Takahashi Y, Takeuchi C, Niimi K, Ono S. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med. 2012;10:45. [PMID: 22554226 DOI: 10.1186/1741-7015-10-45] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
12 Chen CL, Hsu PI. Current advances in the diagnosis and treatment of nonerosive reflux disease. Gastroenterol Res Pract. 2013;2013:653989. [PMID: 23935610 DOI: 10.1155/2013/653989] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
13 Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, Ramsay T, Bai A, Shukla VK, Grimshaw JM. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One. 2007;2:e1350. [PMID: 18159233 DOI: 10.1371/journal.pone.0001350] [Cited by in Crossref: 340] [Cited by in F6Publishing: 321] [Article Influence: 22.7] [Reference Citation Analysis]
14 Mössner J. The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int 2016;113:477-83. [PMID: 27476707 DOI: 10.3238/arztebl.2016.0477] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]